Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 3/20 | 0.53 |
| ▸ | NOS1 | P29475 | 3/20 | 0.53 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.53 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.53 |
| ▸ | AXL | P30530 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.40 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 2/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30194137 | 0.81 | AXL (0.48) | METAP2NOS1CSNK2A1DYRK1AAXL | |
| SCHEMBL2443701 | 0.81 | AXL (0.48) | METAP2NOS1CSNK2A1DYRK1AAXL | |
| SCHEMBL30194080 | 0.79 | NOS1 (0.48) | METAP2NOS1CSNK2A1DYRK1AAXL | |
| SCHEMBL28509646 | 0.79 | NOS1 (0.48) | METAP2NOS1CSNK2A1DYRK1AAXL | |
| SCHEMBL20160340 | 0.78 | MAPK14 (0.43) | NOS1TRPA1FGFR2TLR8MKNK1 | |
| SCHEMBL20155327 | 0.76 | TRPA1 (0.45) | AXLTRPA1FGFR2TLR8 | |
| SCHEMBL27266032 | 0.76 | MAPK1 (0.58) | ALDH1A1MAPTMAPK1TDP1L3MBTL1 | |
| SCHEMBL31371559 | 0.74 | CTNNB1 (0.41) | CSNK2A1DYRK1ATRPA1ROCK1 | |
| SCHEMBL680304 | 0.74 | MAPT (0.53) | NOS1AXLALDH1A1MAPTMAPK1 | |
| SCHEMBL29521071 | 0.73 | AXL (0.60) | AXLTRPA1FGFR2TLR8FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE43878-E1 | Amidophenoxyindazoles useful as inhibitors of c-Met | ELI LILLY AND COMPANY (US) | 2012-12-25 | — | — | US | disclosed |
| EP-2310382-B1 | AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET | LILLY CO ELI (US) | 2012-02-22 | — | — | EP | disclosed |
| US-8030302-B2 | Amidophenoxyindazoles useful as inhibitors of c-Met | ELI LILLY AND COMPANY (US) | 2011-10-04 | — | — | US | disclosed |
| CN-102105462-A | Amidophenoxyindazoles useful as inhibitors of C-MET | LILLY CO ELI | 2011-06-22 | — | — | CN | disclosed |
| EP-2310382-A1 | AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET | Eli Lilly & Company (US) | 2011-04-20 | — | — | EP | disclosed |
| WO-2010011538-A1 | AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET | ELI LILLY AND COMPANY (US) | 2010-01-28 | — | — | WO | disclosed |
| US-20100022529-A1 | AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET | ELI LILLY AND COMPANY | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022529-A1 | AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET | MET, MYCBP, MYC | METAP2 51/4885NOS1 2168/4885CSNK2A1 1403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.